[ad_1]
With nearly two million new cases and 930,000 deaths per year, colorectal cancer is the third most frequently diagnosed cancer in the world, and the second most deadly1. However, early detection and management can improve prognosis. These figures underscore the urgent need to improve prevention and to serve patient needs. Our awareness of these issues has led us to focus on developing innovative projects, for and with patients.
A month to build awareness about colorectal cancer
Servier is joining Digestive Cancers Europe (DiCE), a non-profit organization representing patients, in its annual campaign against colorectal cancer. European Colorectal Cancer Awareness Month, or ECCAM, runs the entire month of March (Blue March). Together, our goal is to contribute to improving colorectal cancer screening programs while offering new initiatives to widely inform and build awareness about the importance of prevention and early detection of the signs and symptoms of this cancer.
Colorectal Cancer: when screening comes too late
Colorectal cancer is a common disease and one of the most widely diagnosed cancers in the world, ranking third behind lung cancer and liver cancer. It affects almost as many women as men1.
Committed to working with patients through the PROMETCO project
At Servier, patients are at the heart of every decision we make. This ambition is symbolized by PROMETCO, the first real-world evidence study in oncology conducted by our teams specifically focused on metastatic colorectal cancer.
Developed jointly with the non-profit patient organization DiCE, PROMETCO will give us a more accurate picture of metastatic colorectal cancer management from the perspective of both patients and physicians.
In the fight against colorectal cancer, PROMETCO is seen as an innovative real-world evidence study. The publication of the study’s expands the current pool of medical knowledge on colorectal cancer and provides invaluable support to medical teams. PROMETCO is thus paving the way toward significant advances in oncology.
In an article published on July 13, 2023 by the medical journal Future Oncology2, PROMETCO was hailed as the first international real-world evidence study on the continuum of care for patients with colorectal cancer.
SHAPE: An initiative with and for patients
Our actions in conjunction with the non-profit patient organization DiCE continue through the international program SHAPE (Support Harmonized Advances for better Patient Experiences). This initiative consists in providing patient support through various means, including brochures designed jointly with patient advocates. These brochures cover the crucial aspects of living day-to-day with the disease and include numerous tips.
Our involvement in SHAPE illustrates an inclusive approach to improving patients’ lives. By combining our skills and giving a voice to people who are directly impacted, together we are striving to build a future where patient support is the result of true cooperation between Servier, health care professionals, and patients or their caregivers.
[1] OMS – Fact Sheet – Cancer Cancer (who.int)
[2] Real-world evidence research in metastatic colorectal cancer: raising awareness of the need for patient contributions – Future Oncology, July 2023